Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

19 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Galenica Articles

Vifor gets certain rights to Helsinn's netupitant-palonosetron

16 May 2013

US FDA sets new PDUFA action date for Vifor's Injectafer NDA

8 April 2013

Vifor Fresenius PA21 filed for approval with US FDA, accepted by EMA

11 February 2013

Observational study suggests a role for Vifor's Ferinject for anemic and iron deficient patients with cancer

31 January 2013

Teijin debuts Ipsen's Somatuline in Japan; Galenica deal for Maltofer and Uro-Vaxom in China

18 January 2013

Regulatory filing preparations underway for Vifor's PA21 on good Ph III results

9 July 2012

Vifor to distribute Debiopharm's Pamorelin in Switzerland

15 May 2012

Galenica acquires Spanish JV Vifor Uriach and Grupo Uriach's primary care business

15 November 2011

Vifor Pharma ties up with Hikma for Ferinject in Middle East and North Africa

17 August 2011

Showing 1-9 of 9 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
  • Daiichi Sankyo files for Japanese approval of Prasugrel
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
  • Daiichi Sankyo files for Japanese approval of Prasugrel
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS